Pharmacy Services Alerts
Senna Laxative Tablets Mislabeling Recall - Bottle Contains Naproxen
Jan 29, 2018 10:48 AM
**Due to an update in May 2019 to the FDA.gov website, provided links may not appropriately redirect. Please visit www.fda.gov/drugs/drug-safety-and-availability to see the most recent FDA Medication Safety Alerts and Safety Communications or to search for specific alerts or communications.**
Magno-Humphries Laboratories Inc is voluntarily recalling Basic Drugs Brand Senna Laxative tablets due to mislabeling concerns. This recall affects 1 lot of 100-count bottles (Lot 352300, Exp 1/2019). This lot contains naproxen sodium 220 mg tablets, but is labeled as Senna Laxative tablets (sennosides 8.6 mg). Senna is a laxative for constipation relief. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used as a pain reliever. Unintentional use of naproxen with other NSAIDs increases the likelihood of adverse events, such as myocardial infarction, stroke, congestive heart failure, renal toxicity, bleeding, or gastrointestinal ulceration or perforation. Patients may also experience adverse effects related to underlying chronic conditions, such as cardiac, gastrointestinal, renal and hepatic conditions. Magno-Humphries Laboratories Inc has not received any reports of adverse events due to the mislabeling.
Magno-Humphries Laboratories Inc has notified their distributor by email to arrange the return of the mislabeled lot. Distribution centers, retail pharmacies and internet retailers have potentially distributed the affected lot. Consumers with questions regarding this recall may contact Magno-Humphries Laboratories Inc by phone at (503-684-5464 or 800-935-6737) or email (firstname.lastname@example.org). Consumers should report any adverse reactions experienced from this product to their provider and the FDA MedWatch Adverse Event Reporting program.
- MedWatch Safety Alert – January 22, 2018
- Magno-Humphries Laboratories, Inc. press release – January 19, 2018